Table 1 Characteristics of 35 HER2 negative mBC patients treated with Bevacizumab plus Paclitaxel followed by maintenance Bevacizumab
Total number of patients (n = 35) | Frequency (%) |
|---|---|
Median age (range) | 50 (32–72) |
Menopausal Status | |
Pre | 6 (17.1) |
Post | 29 (82.9) |
Hormonal Receptor Status | |
Negative | 5 (14.3) |
Positive | 30 (85.7) |
Triple negative | 5 (14.3) |
Adjuvant chemotherapy | |
- None | 13 (37.1) |
- including anthracyclines | 9 (25.7) |
- including antracyclines + taxanes | 9 (25.7) |
- Other regimens | 4 (11.4) |
Adjuvant hormonal therapy | 22 (62.8) |
Visceral metastatic sites | 23 (65.7) |
Median Disease Free Survival, months (range) | 30 (0–362) |
Median Cycles of Bevacizumab + Paclitaxel (range) | 8 (6–12) |
Median cycles of three-weekly mBev (range) | 7 (1 – 28) |
Median PS at the start of mBev (range) | 0 (0–1) |